TY - JOUR
T1 - Update on Transcatheter Tricuspid Valve Replacement Therapies
AU - Goldberg, Ythan H.
AU - Ho, Edwin
AU - Chau, Mei
AU - Latib, Azeem
N1 - Funding Information:
The TRiCares (TRiCares SAS, Paris, France, ) is a bovine pericardial self-expanding valve mounted on a nitinol frame. Though still early in its development, it received 2020 grant funding from the European Innovation Council to bring its product into the clinical realm.
Publisher Copyright:
Copyright © 2021 Goldberg, Ho, Chau and Latib.
PY - 2021/2/15
Y1 - 2021/2/15
N2 - Severe tricuspid regurgitation is relatively common, especially in the elderly, and portends poor survival. Neither medical therapy nor conventional surgery is efficacious for most patients. In contrast, transcatheter tricuspid valve interventions are showing promise to improve quality of life and mortality. Although there is more clinical experience with transcatheter tricuspid valve repair, there are many patients for which repair is either not possible or cannot optimally reduce the severity of tricuspid regurgitation. Transcatheter tricuspid valve replacement is rapidly emerging and may ultimately become the preferred treatment option. In this review, we discuss transcatheter tricuspid valve replacement, analyze the devices in development and in clinical trials, and highlight the advantages and drawbacks of transcatheter tricuspid valve replacement vs. repair.
AB - Severe tricuspid regurgitation is relatively common, especially in the elderly, and portends poor survival. Neither medical therapy nor conventional surgery is efficacious for most patients. In contrast, transcatheter tricuspid valve interventions are showing promise to improve quality of life and mortality. Although there is more clinical experience with transcatheter tricuspid valve repair, there are many patients for which repair is either not possible or cannot optimally reduce the severity of tricuspid regurgitation. Transcatheter tricuspid valve replacement is rapidly emerging and may ultimately become the preferred treatment option. In this review, we discuss transcatheter tricuspid valve replacement, analyze the devices in development and in clinical trials, and highlight the advantages and drawbacks of transcatheter tricuspid valve replacement vs. repair.
KW - experimental devices
KW - structural valvular heart disease
KW - transcatheter valve implantation
KW - tricuspid regurgitation
KW - tricuspid valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85107213315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107213315&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2021.619558
DO - 10.3389/fcvm.2021.619558
M3 - Review article
AN - SCOPUS:85107213315
SN - 2297-055X
VL - 8
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
M1 - 619558
ER -